Alaproclate
Systematic (IUPAC) name
1-(4-chlorophenyl)-2-methylpropan-2-yl 2-aminopropanoate
Clinical data
Pregnancy cat.  ?
Legal status Uncontrolled
Routes Oral
Identifiers
CAS number 60719-82-6
60719-83-7 (hydrochloride)
ATC code N06AB07
PubChem CID 2081
ChemSpider 1997 YesY
UNII C4R42570ZO YesY
KEGG D02787 YesY
ChEMBL CHEMBL36591 YesY
Chemical data
Formula C13H18ClNO2 
Mol. mass 255.740 g/mol
SMILES eMolecules & PubChem
 YesY (what is this?)  (verify)

Alaproclate (GEA-654) is a psychoactive drug and research chemical that was being developed as an antidepressant by the Swedish pharmaceutical company Astra AB (now AstraZeneca) in the 1970s. It acts as a selective serotonin reuptake inhibitor (SSRI), and along with zimelidine and indalpine, was one of the first of its kind. Development was discontinued due to the observation of liver complications in rodent studies. Some studies have found that it acts as a noncompetitive NMDA antagonist, but does not have discriminative stimulus properties similar to phencyclidine.[1][2]

See also [link]

References [link]

  1. ^ A Wilkinson, M Courtney, A Westlind-Danielsson, G Hallnemo and K E Akerman (December). "Alaproclate acts as a potent, reversible and noncompetitive antagonist of the NMDA receptor coupled ion flow". JPET 271 (3): 1314–1319. 
  2. ^ K L Nicholson and R L Balster (23 April). "Evaluation of the phencyclidine-like discriminative stimulus effects of novel NMDA channel blockers in rats". Psychopharmacology. 
GABAA PAMs
Others
α2δ VDCC Blockers
5-HT1A Agonists
H1 Antagonists
CRH1 Antagonists
NK2 Antagonists
MCH1 antagonists
mGluR2/3 Agonists
mGluR5 NAMs
TSPO agonists
σ1 agonists
Others

M: PSO/PSI

dsrd (o, p, m, p, a, d, s), sysi/epon, spvo

proc(eval/thrp), drug(N5A/5B/5C/6A/6B/6D)


Stub icon This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

https://wn.com/Alaproclate

Podcasts:

Email this Page Play all in Full Screen Show More Related Videos
PLAYLIST TIME:
×
×
×
×